Francesc Baró-Mariné, Antonia Pijuan-Domènech, Maria Del Mar Goya, Elena Suárez-Edo, Berta Miranda-Barrio, Laura Dos-Subirà, Maria Luisa Pancorbo, Ignacio Ferreira-Gonzalez, Elena Carreras-Moratonas
{"title":"患有先天性心脏病的妇女仅使用孕激素避孕。","authors":"Francesc Baró-Mariné, Antonia Pijuan-Domènech, Maria Del Mar Goya, Elena Suárez-Edo, Berta Miranda-Barrio, Laura Dos-Subirà, Maria Luisa Pancorbo, Ignacio Ferreira-Gonzalez, Elena Carreras-Moratonas","doi":"10.1080/01443615.2024.2320296","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.</p><p><strong>Objective: </strong>To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).</p><p><strong>Study design: </strong>Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.</p><p><strong>Results: </strong>Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (<i>p</i> < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.</p><p><strong>Conclusions: </strong>Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.</p>","PeriodicalId":16627,"journal":{"name":"Journal of Obstetrics and Gynaecology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progestogen only contraception in women with congenital heart disease.\",\"authors\":\"Francesc Baró-Mariné, Antonia Pijuan-Domènech, Maria Del Mar Goya, Elena Suárez-Edo, Berta Miranda-Barrio, Laura Dos-Subirà, Maria Luisa Pancorbo, Ignacio Ferreira-Gonzalez, Elena Carreras-Moratonas\",\"doi\":\"10.1080/01443615.2024.2320296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.</p><p><strong>Objective: </strong>To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).</p><p><strong>Study design: </strong>Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.</p><p><strong>Results: </strong>Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (<i>p</i> < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.</p><p><strong>Conclusions: </strong>Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.</p>\",\"PeriodicalId\":16627,\"journal\":{\"name\":\"Journal of Obstetrics and Gynaecology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Obstetrics and Gynaecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/01443615.2024.2320296\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynaecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01443615.2024.2320296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Progestogen only contraception in women with congenital heart disease.
Background: There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.
Objective: To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).
Study design: Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.
Results: Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (p < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.
Conclusions: Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.
期刊介绍：
Journal of Obstetrics and Gynaecology represents an established forum for the entire field of obstetrics and gynaecology, publishing a broad range of original, peer-reviewed papers, from scientific and clinical research to reviews relevant to practice. It also includes occasional supplements on clinical symposia. The journal is read widely by trainees in our specialty and we acknowledge a major role in education in Obstetrics and Gynaecology. Past and present editors have recognized the difficulties that junior doctors encounter in achieving their first publications and spend time advising authors during their initial attempts at submission. The journal continues to attract a world-wide readership thanks to the emphasis on practical applicability and its excellent record of drawing on an international base of authors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
